However, this drug is unlikely to be effective in tumors dependent on BCL-XL rather than BCL-2 (eg ovarian cancer, [113]) and we speculate that BCL-XL will emerge as a mechanism of resistance to ABT-199. Here, BCL2L1 is linked to ovarian carcinoma.